J&J’s Codman Neuro snaps up stroke-care company Neuravi for undisclosed price

The Neuravi deal is the biggest payout for a venture-backed med-tech company in Europe since the $700 million deal for CoreValve by Medtronic in 2009.

Johnson & Johnson unit Codman Neuro has picked up privately held Galway, Ireland-based stroke care company Neuravi for an undisclosed price, giving J&J an avenue into the quickly growing market for the treatment of acute ischemic stroke patients.

DePuy Ireland Unlimited, an affiliate of Codman, is the acquiring entity of record, the company said. Although details of the acquisition weren’t disclosed, the Irish Times reported that the Neuravi deal is the biggest payout for a venture-backed medtech company in Europe since the $700 million deal for CoreValve by Medtronic in 2009.

Neuravi, which was founded the same year as the CoreValve deal, developed the EmboTrap device that captures and removes clots from blood vessels and restores blood flow. The process of retrieving blood clots by device has become the industry standard versus using lipid drugs that were effective only with smaller clots. Ischemic stroke represent about 87% of all strokes, which affect an estimated 1 million people in Europe and about 700,000 in the U.S. each year.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"Rapid restoration of flow is of utmost importance when treating stroke patients," Shlomi Nachman, group chairman Johnson & Johnson Medical Devices Cardiovascular & Specialty Solutions, said in a statement. "The EmboTrap platform was designed to address this critical need and we are excited to combine Neuravi's expertise in clot research with Codman Neuro's global resources to accelerate innovation in acute ischemic stroke treatment."

The EmboTrap and EmboTrap II Revascularization Devices are currently available in Europe and has been available in the U.S. for investigational use only under the ARISE II clinical trial, which will support a FDA submission expected for later this year, the company said.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.